Does the MTRR rs1801394 variant raise homocysteine when folate or vitamin B12 is low?

The MTRR rs1801394 variant is closely linked to altered one-carbon metabolism, but its clinical significance is heavily dictated by nutritional status.

Mechanistic explanations

• Enzyme Dysfunction: The MTRR rs1801394 (A66G) polymorphism causes an isoleucine-to-methionine substitution (Ile22Met) in the N-terminal FMN-binding domain of methionine synthase reductase (MTRR).
• Reduced Catalytic Efficiency: This structural shift results in a 35% to 40% reduction in catalytic efficiency ($k_{cat}/K_m$). Because MTRR is biochemically required to regenerate and maintain methionine synthase (MTR) in its active, methylcobalamin-bound state, this variant directly compromises the remethylation of homocysteine to methionine.

Clinical and nutritional interactions

• Nutrient Dependency: The rs1801394 G allele (particularly the homozygous GG genotype) has a modest independent effect on baseline total homocysteine in individuals with sufficient nutrient status.
• Exacerbation by Deficiency: When folate or vitamin B12 levels are low, the metabolic margin of safety is exceeded. A lack of folate substrates or cobalamin cofactors, combined with reduced MTRR catalytic activity, severely bottlenecks the remethylation pathway, driving homocysteine accumulation.
• Riboflavin Role: Because MTRR is an FMN-containing flavoprotein, riboflavin (vitamin B2) status also interacts with this pathway; maintaining adequate riboflavin levels is necessary to support optimal enzyme stability and function.

Bottom line

• The MTRR rs1801394 variant reduces enzyme efficiency by 35–40%, which significantly elevates homocysteine levels when folate or vitamin B12 levels are suboptimal. Optimizing intake of folate, vitamin B12, and riboflavin is highly effective at overcoming this genetic bottleneck and maintaining healthy homocysteine levels.